Login
$ELDN
$2.01 +$0.04 (2.23%) After hours

$ELDN SEC Filings

Filed On Filing
12 Nov 2026 10-Q
12 Nov 2026 8-K: Results of Operations and Financial Condition

Planned global Phase 3 LEGACY trial of tegoprubart in kidney transplantation remains on track to initiate in Q4 2026

30 Oct 2026 SCHEDULE 13G/A
04 Sep 2026 S-8
13 Aug 2026 10-Q
13 Aug 2026 8-K: Results of Operations and Financial Condition

Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026

04 Aug 2026 Form 4: Gros David-Alexandre C, Director

Received 354,454 shares as a grant or award · Gave up 194,791 shares to cover exercise price or tax ($658K)

04 Aug 2026 Form 4: Perrin Steven, Director

Received 152,353 shares as a grant or award · Gave up 72,138 shares to cover exercise price or tax ($244K)

31 Jul 2026 SCHEDULE 13G
22 Jun 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

Eledon Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as ...

15 May 2026 SCHEDULE 13G/A
13 May 2026 10-Q
13 May 2026 8-K: Results of Operations and Financial Condition

100% insulin independence achieved in 10 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study

11 May 2026 EFFECT
07 May 2026 CORRESP
07 May 2026 UPLOAD
01 May 2026 S-3
30 Apr 2026 DEFA14A
30 Apr 2026 ARS
30 Apr 2026 Proxy statement: annual meeting on June 18, 2026

CEO pay $3.2M, down 43%

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support